Dupixent cancer cases are being filed as product liability lawsuits against the drug companies Sanofi and Regeneron, based on various allegations concerning the Defendants’ failure to warn patients and their doctors about an increased risk of T-cell lymphoma, which appears to be a Dupixent-related side effect.
In summary, these Dupixent cancer cases against Sanofi and Regeneron are based on their wrongful conduct in connection with the development, testing, labeling, packaging, promotion, advertising, marketing, distribution, and selling of Dupixent (dupilumab).
Some of the allegations contained in the lawsuits for Dupixent cancer cases are:
- Defendants Regeneron and Sanofi knew or should have known of the potential of Dupixent to exacerbate or accelerate pre-existing T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), or increase susceptibility to its development.
- Defendants failed to adequately test Dupixent to investigate the risks, including the potential of exacerbating pre-existing T-cell lymphoma or increasing susceptibility to its development.
- Defendants failed to warn physicians and patients that Dupixent should not be prescribed or administered to patients with confirmed or suspected T-cell lymphoma, including CTCL and PTCL.
As background, here is some basic medical information relevant to these Dupixent cancer cases:
- There are several types of T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
- CTCL is a T-cell lymphoma that begins in the skin. Mycosis fungoides and Sézary syndrome are the two most common subtypes of CTCL.
- PTCL refers to systemic T-cell lymphomas that are found in the lymph nodes, other organs, and the blood. Also, some types involve the skin.
- T-cell lymphomas, both CTCL and PTCL, are a subtype of non-Hodgkin lymphoma (NHL).
We are currently investigating possible Dupixent cancer cases for patients who were diagnosed with one of the following medical conditions, some time after they started using Dupixent:
- T-cell lymphoma
- Cutaneous T-cell lymphoma (CTCL)
- Peripheral T-cell lymphoma (PTCL)
- Mycosis fungoides
- Sézary syndrome
For individuals with a Dupixent-related cancer case, we encourage them to submit a Dupixent Cancer Case Evaluation Form online or call 910-256-2971 to discuss their potential case with attorney Tom Lamb.
[Read the article in full at source]Dupixent
Free Case Evaluation
Strictly Confidential, No Obligation